One-stage prosthesis exchange for Candida joint infections
Official title: One-stage Exchange in Candida Periprosthetic Infection a Suitable Way to go
Run by University Hospital, Strasbourg, France · NCT07303101 · Data updated 2026-11-12
This project tests whether replacing an infected hip or knee prosthesis in a single operation helps adults with Candida joint infections.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 16 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | May 28, 2025 |
| Main results expected | February 2026 |
| Study ends | February 2026 |
| Registry record updated | December 24, 2025 |
| Trial ID | NCT07303101 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (>18) who had hip or knee prosthesis revision at CHU Strasbourg between 2013 and 2021 with possible or proven Candida periprosthetic infection (EBJIS criteria), at least three deep samples, and who received systemic antifungal therapy.
✕Probably not a fit
Patients managed with implant retention (lavage/synovectomy), those with concurrent Candida infections elsewhere or endocarditis, patients on suppressive antifungal therapy before surgery, or those who did not receive systemic antifungals are unlikely to benefit from one-stage exchange in this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective observational analysis of adults who underwent hip or knee prosthesis revision at Strasbourg University Hospitals between January 1, 2013 and December 31, 2021 with possible or proven Candida periprosthetic infection according to EBJIS criteria. Included patients are over 18, had at least three deep microbiologic samples (joint fluid, preoperative tissue, or prosthesis sonication), and received systemic antifungal treatment after implant exchange. The analysis describes outcomes after one-stage prosthesis exchange and compares observed success rates with those reported for two-stage replacement in the literature. Systemic antifungal regimens and surgical details are recorded but expected to be heterogeneous, and prior evidence is limited to small retrospective series.
Why it matters
Potential benefit: If successful, this approach could allow some patients to be cured with a single operation, reducing recovery time, hospital stays, and overall treatment burden.
How similar studies have gone: Only three small retrospective single-center reports have examined one-stage exchange for Candida periprosthetic infection, reporting 2-year success rates around 63–81% that are similar to ranges reported for two-stage replacement, but overall evidence remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged over 18 years at the time of prosthesis revision * Operated on at the Strasbourg University Hospitals (HUS) between January 1, 2013, and December 31, 2021 * Hip or knee prosthesis revision * Possible or proven periprosthetic Candida spp. infection according to the EBJIS diagnostic criteria * Minimum of 3 deep samples (joint fluid, preoperative sample, and/or prosthesis sonication) Exclusion Criteria: * Patient undergoing lavage, synovectomy, and implant preservation * Patient not receiving systemic antifungal treatment after prosthesis replacement * Patient with another proven Candida spp. infection or infective endocarditis * Patient for whom suppressive therapy was prescribed prior to surgery.
Where it's running
-
Service de Chirurgie Orthopédique Septique - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Stéphane Klein, MD
- Email: stephane.klein@chru-strasbourg.fr
- Phone: 33 3 68 76 52 32
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating the safety of ibrexafungerp in pregnant women and their infants
This study is testing whether ibrexafungerp is safe for pregnant women and their babies by looking at their health during and after pregnancy.
-
Early oral thrush and baby tooth decay
This study will see if having oral thrush in the first year of life is linked to earlier or more severe tooth decay in infants and toddlers.
-
Patient-specific biomechanical modeling of incisional hernias with AI and finite element analysis
Researchers will test a personalized computer model of the abdominal wall for adults with incisional hernias using anonymized CT data and AI to see how the hernia shapes relate to tissue mechanics.
-
Menin inhibitors in pediatric relapsed or refractory acute leukemia
This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.
-
Long-Term Epilepsy Outcomes in Children After Perinatal Stroke
This study looks at how epilepsy progresses in kids who had a stroke before 28 days old to see how their seizures and syndromes evolve over time.
-
Predictors of Success and Failure of v-NOTES Hysterectomy for Large Uteri
This study looks at which factors predict whether a v-NOTES hysterectomy for large uteri will be completed without needing to switch to another surgical approach.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.